FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2156873443> ?p ?o ?g. }

• W2156873443 endingPage "151" @default.
• W2156873443 startingPage "151" @default.
• W2156873443 abstract "To The Editor:Filocamo et al reported the use of infliximab as adjunctive therapy for treating Takayasu's disease.1Filocamo G. Buoncompagni A. Viola S. Loy A. Malattia C. Ravelli A. et al.Treatment of Takayasu's arteritis with tumor necrosis factor antagonists.J Pediatr. 2008; 153: 432-434Abstract Full Text Full Text PDF PubMed Scopus (43) Google Scholar Recently, we treated a 15-year-old girl who presented with weight loss, abdominal pain, and severe oral and perianal manifestations. The results of initial blood investigations showed high levels of inflammatory markers with a low albumin level. The diagnosis of perianal and ileo-colonic Crohn's disease was confirmed with endoscopy, ileo-colonoscopy, and biopsies. The presence of 1 perianal fistula was confirmed with magnetic resonance imaging. The patient failed to comply with nutritional therapy, and so she was given steroids and azathioprine. However, a few months later, she relapsed, and, after discussion with her and her family, infliximab (5 mg/kg) was started. She did well while taking infliximab and after. Despite recent infliximab maintenance (every 6-8 weeks), a few months later she had fever, headache, vomiting, and abdominal pain. Her blood pressure was in the reference range. She was given intravenous antibiotics, despite negative results on several infection screens. No evidence of the relapse of Crohn's disease was shown with an endoscopy and colonoscopy. Abdominal computed tomography was performed to exclude intra-abdominal collections, and some thickening of the abdominal aorta was shown, which was confirmed with a magnetic resonance imaging angiogram. A diagnosis of Takayasu's disease was confirmed, and the patient responded to systemic intravenous steroids.In this case, acute manifestations of Takayasu's disease developed while the patient was receiving 5 mg/kg of infliximab every 6 to 8 weeks with azathioprine. Several reports documented the success of infliximab in treating Takayasu's disease with or without other immunosuppressant, even when the patient is resistant to steroids.2Tanaka F. Kawakami A. Iwanaga N. Tamai M. Izumi Y. Aratake K. et al.Infliximab is effective for Takayasu arteritis refractory to glucocorticoid and methotrexate.Intern Med. 2006; 45: 313-316Crossref PubMed Scopus (55) Google Scholar, 3Karageorgaki Z.T. Mavragani C.P. Papathanasiou M.A. Skopouli F.N. Infliximab in Takayasu arteritis: a safe alternative?.Clin Rheumatol. 2007; 26: 984-987Crossref PubMed Scopus (39) Google Scholar Some reports even used doses of infliximab lower than 3 mg/kg.3Karageorgaki Z.T. Mavragani C.P. Papathanasiou M.A. Skopouli F.N. Infliximab in Takayasu arteritis: a safe alternative?.Clin Rheumatol. 2007; 26: 984-987Crossref PubMed Scopus (39) Google Scholar We are not sure whether having Crohn's disease in addition to Takayasu's disease would make the latter difficult to control. There are a number of reports in the literature reporting the association of these 2 conditions,4Kellermayer R. Jain A.K. Ferry G. Clinical challenges and images in GI. Aortitis as a rare complication of Crohn's disease.Gastroenterology. 2008; 134: 668-898Abstract Full Text Full Text PDF PubMed Scopus (2) Google Scholar, 5Farrant M. Mason J.C. Wong N.A. Longman R.J. Takayasu's arteritis following Crohn's disease in a young woman: any evidence for a common pathogenesis?.World J Gastroenterol. 2008; 14: 4087-4090Crossref PubMed Scopus (20) Google Scholar, 6Reny J.L. Paul J.F. Lefèbvre C. Champion K. Emmerich J. Bletry O. et al.Association of Takayasu's arteritis and Crohn's disease. Results of a study on 44 Takayasu patients and review of the literature.Ann Med Interne (Paris). 2003; 154: 85-90PubMed Google Scholar but the significance of this association has yet to be defined. Infliximab in this patient did not prevent the development of acute symptoms of Takayasu's disease. To The Editor: Filocamo et al reported the use of infliximab as adjunctive therapy for treating Takayasu's disease.1Filocamo G. Buoncompagni A. Viola S. Loy A. Malattia C. Ravelli A. et al.Treatment of Takayasu's arteritis with tumor necrosis factor antagonists.J Pediatr. 2008; 153: 432-434Abstract Full Text Full Text PDF PubMed Scopus (43) Google Scholar Recently, we treated a 15-year-old girl who presented with weight loss, abdominal pain, and severe oral and perianal manifestations. The results of initial blood investigations showed high levels of inflammatory markers with a low albumin level. The diagnosis of perianal and ileo-colonic Crohn's disease was confirmed with endoscopy, ileo-colonoscopy, and biopsies. The presence of 1 perianal fistula was confirmed with magnetic resonance imaging. The patient failed to comply with nutritional therapy, and so she was given steroids and azathioprine. However, a few months later, she relapsed, and, after discussion with her and her family, infliximab (5 mg/kg) was started. She did well while taking infliximab and after. Despite recent infliximab maintenance (every 6-8 weeks), a few months later she had fever, headache, vomiting, and abdominal pain. Her blood pressure was in the reference range. She was given intravenous antibiotics, despite negative results on several infection screens. No evidence of the relapse of Crohn's disease was shown with an endoscopy and colonoscopy. Abdominal computed tomography was performed to exclude intra-abdominal collections, and some thickening of the abdominal aorta was shown, which was confirmed with a magnetic resonance imaging angiogram. A diagnosis of Takayasu's disease was confirmed, and the patient responded to systemic intravenous steroids. In this case, acute manifestations of Takayasu's disease developed while the patient was receiving 5 mg/kg of infliximab every 6 to 8 weeks with azathioprine. Several reports documented the success of infliximab in treating Takayasu's disease with or without other immunosuppressant, even when the patient is resistant to steroids.2Tanaka F. Kawakami A. Iwanaga N. Tamai M. Izumi Y. Aratake K. et al.Infliximab is effective for Takayasu arteritis refractory to glucocorticoid and methotrexate.Intern Med. 2006; 45: 313-316Crossref PubMed Scopus (55) Google Scholar, 3Karageorgaki Z.T. Mavragani C.P. Papathanasiou M.A. Skopouli F.N. Infliximab in Takayasu arteritis: a safe alternative?.Clin Rheumatol. 2007; 26: 984-987Crossref PubMed Scopus (39) Google Scholar Some reports even used doses of infliximab lower than 3 mg/kg.3Karageorgaki Z.T. Mavragani C.P. Papathanasiou M.A. Skopouli F.N. Infliximab in Takayasu arteritis: a safe alternative?.Clin Rheumatol. 2007; 26: 984-987Crossref PubMed Scopus (39) Google Scholar We are not sure whether having Crohn's disease in addition to Takayasu's disease would make the latter difficult to control. There are a number of reports in the literature reporting the association of these 2 conditions,4Kellermayer R. Jain A.K. Ferry G. Clinical challenges and images in GI. Aortitis as a rare complication of Crohn's disease.Gastroenterology. 2008; 134: 668-898Abstract Full Text Full Text PDF PubMed Scopus (2) Google Scholar, 5Farrant M. Mason J.C. Wong N.A. Longman R.J. Takayasu's arteritis following Crohn's disease in a young woman: any evidence for a common pathogenesis?.World J Gastroenterol. 2008; 14: 4087-4090Crossref PubMed Scopus (20) Google Scholar, 6Reny J.L. Paul J.F. Lefèbvre C. Champion K. Emmerich J. Bletry O. et al.Association of Takayasu's arteritis and Crohn's disease. Results of a study on 44 Takayasu patients and review of the literature.Ann Med Interne (Paris). 2003; 154: 85-90PubMed Google Scholar but the significance of this association has yet to be defined. Infliximab in this patient did not prevent the development of acute symptoms of Takayasu's disease." @default.
• W2156873443 created "2016-06-24" @default.
• W2156873443 creator A5006121400 @default.
• W2156873443 creator A5007042171 @default.
• W2156873443 date "2009-07-01" @default.
• W2156873443 modified "2023-10-18" @default.
• W2156873443 title "Takayasu's aortitis and infliximab" @default.
• W2156873443 cites W1979611102 @default.
• W2156873443 cites W2007228319 @default.
• W2156873443 cites W2025282979 @default.
• W2156873443 cites W2046644626 @default.
• W2156873443 cites W92761568 @default.
• W2156873443 doi "https://doi.org/10.1016/j.jpeds.2009.01.056" @default.
• W2156873443 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19559311" @default.
• W2156873443 hasPublicationYear "2009" @default.
• W2156873443 type Work @default.
• W2156873443 sameAs 2156873443 @default.
• W2156873443 citedByCount "7" @default.
• W2156873443 countsByYear W21568734432013 @default.
• W2156873443 countsByYear W21568734432014 @default.
• W2156873443 countsByYear W21568734432015 @default.
• W2156873443 countsByYear W21568734432017 @default.
• W2156873443 crossrefType "journal-article" @default.
• W2156873443 hasAuthorship W2156873443A5006121400 @default.
• W2156873443 hasAuthorship W2156873443A5007042171 @default.
• W2156873443 hasConcept C126322002 @default.
• W2156873443 hasConcept C17991360 @default.
• W2156873443 hasConcept C2776015282 @default.
• W2156873443 hasConcept C2777138892 @default.
• W2156873443 hasConcept C2777818683 @default.
• W2156873443 hasConcept C2779134260 @default.
• W2156873443 hasConcept C2779980429 @default.
• W2156873443 hasConcept C3019145103 @default.
• W2156873443 hasConcept C71924100 @default.
• W2156873443 hasConceptScore W2156873443C126322002 @default.
• W2156873443 hasConceptScore W2156873443C17991360 @default.
• W2156873443 hasConceptScore W2156873443C2776015282 @default.
• W2156873443 hasConceptScore W2156873443C2777138892 @default.
• W2156873443 hasConceptScore W2156873443C2777818683 @default.
• W2156873443 hasConceptScore W2156873443C2779134260 @default.
• W2156873443 hasConceptScore W2156873443C2779980429 @default.
• W2156873443 hasConceptScore W2156873443C3019145103 @default.
• W2156873443 hasConceptScore W2156873443C71924100 @default.
• W2156873443 hasIssue "1" @default.
• W2156873443 hasLocation W21568734431 @default.
• W2156873443 hasLocation W21568734432 @default.
• W2156873443 hasOpenAccess W2156873443 @default.
• W2156873443 hasPrimaryLocation W21568734431 @default.
• W2156873443 hasRelatedWork W1989246448 @default.
• W2156873443 hasRelatedWork W2034536484 @default.
• W2156873443 hasRelatedWork W2034945806 @default.
• W2156873443 hasRelatedWork W2156873443 @default.
• W2156873443 hasRelatedWork W2163972817 @default.
• W2156873443 hasRelatedWork W2273630113 @default.
• W2156873443 hasRelatedWork W2608058481 @default.
• W2156873443 hasRelatedWork W2978650559 @default.
• W2156873443 hasRelatedWork W4225828223 @default.
• W2156873443 hasRelatedWork W4252131880 @default.
• W2156873443 hasVolume "155" @default.
• W2156873443 isParatext "false" @default.
• W2156873443 isRetracted "false" @default.
• W2156873443 magId "2156873443" @default.
• W2156873443 workType "article" @default.